Inari Medical, Inc. (NASDAQ:NARI) Receives $61.80 Consensus Target Price from Analysts

Inari Medical, Inc. (NASDAQ:NARI) has been given an average rating of “Hold” by the fourteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Twelve equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $68.00.

Several equities analysts recently issued reports on NARI shares. Oppenheimer started coverage on Inari Medical in a research note on Tuesday, December 17th. They set an “outperform” rating and a $75.00 price target on the stock. Needham & Company LLC restated a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th. William Blair reaffirmed a “market perform” rating on shares of Inari Medical in a research report on Tuesday, January 7th. Canaccord Genuity Group reiterated a “hold” rating and set a $80.00 price target (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, Piper Sandler increased their price objective on shares of Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a research note on Tuesday, January 7th.

Insider Buying and Selling

In other news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the transaction, the chief executive officer now owns 439,310 shares in the company, valued at approximately $24,289,449.90. The trade was a 0.68 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William Hoffman sold 40,000 shares of the stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00. Following the sale, the director now owns 601,233 shares in the company, valued at approximately $27,067,509.66. This trade represents a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 406,000 shares of company stock worth $22,621,870 in the last quarter. 10.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Inari Medical

Several institutional investors have recently bought and sold shares of NARI. GAMMA Investing LLC grew its holdings in shares of Inari Medical by 66.8% during the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock worth $100,000 after purchasing an additional 786 shares during the last quarter. Franklin Resources Inc. lifted its position in Inari Medical by 2.2% during the 3rd quarter. Franklin Resources Inc. now owns 223,810 shares of the company’s stock worth $9,445,000 after buying an additional 4,899 shares in the last quarter. Barclays PLC grew its holdings in Inari Medical by 9.7% during the 3rd quarter. Barclays PLC now owns 288,079 shares of the company’s stock worth $11,881,000 after acquiring an additional 25,365 shares during the last quarter. Y Intercept Hong Kong Ltd increased its position in Inari Medical by 316.7% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 44,318 shares of the company’s stock valued at $1,828,000 after acquiring an additional 33,682 shares in the last quarter. Finally, Jane Street Group LLC increased its position in Inari Medical by 32.4% in the 3rd quarter. Jane Street Group LLC now owns 95,223 shares of the company’s stock valued at $3,927,000 after acquiring an additional 23,286 shares in the last quarter. Institutional investors own 90.98% of the company’s stock.

Inari Medical Price Performance

NASDAQ NARI opened at $79.34 on Tuesday. The company’s fifty day moving average is $54.72 and its two-hundred day moving average is $49.63. The firm has a market capitalization of $4.64 billion, a price-to-earnings ratio of -58.77 and a beta of 0.97. Inari Medical has a 52-week low of $36.73 and a 52-week high of $79.69.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.